Intensity Therapeutics upsizes proposed IPO to $15M from $8M (INTS)

Oncology drug developer Intensity Therapeutics (NASDAQ:INTS) has upsized its proposed initial public offering to $15M from $8M.

The biotech company said in a filing that it’s now considering offering 3.25M shares priced between $4 and $5, which would raise around $15M if priced at the midpoint. Underwriters would be granted a 45-day option to buy up to 488K additional shares at the IPO price to cover any over-allotments.